Undisclosed liver mRNA target

The term "Undisclosed liver mRNA target" refers to a proprietary messenger RNA sequence expressed in hepatocytes that is being investigated as a therapeutic target but has not yet been publicly identified by the developing pharmaceutical company. In the biotechnology industry, companies like Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals frequently use this placeholder in their pipelines for programs in the early stages of development or those protected by strategic partnerships. These targets are typically addressed using RNA-based modalities, such as small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs), which are designed to bind to the target mRNA and trigger its degradation or inhibit its translation. The liver is a preferred site for such therapies because of the highly efficient delivery enabled by N-acetylgalactosamine (GalNAc) conjugation, which specifically targets the asialoglycoprotein receptor (ASGPR) on the surface of liver cells. While the specific biological function depends on the identity of the gene, these programs generally aim to treat chronic conditions like non-alcoholic steatohepatitis (NASH), hypertension, or rare metabolic deficiencies by silencing the production of disease-driving proteins.

Other names

Undisclosed liver targetProprietary liver mRNA targetUndisclosed hepatocyte mRNA

RNA interference (RNAi) or Antisense oligonucleotide (ASO) mediated gene silencing